Ozone autohemotherapy is a procedure that treats blood outside the body with oxygen and ozone before intravenous reinfusion, studied for pain, fatigue, and impaired function. Benefits reported in people with illness do not establish longer life, disease prevention, or better performance in healthy adults. Serious blood-cell, circulation, and heart-rhythm events have been reported; their true frequency and the consequences of years of repeated treatment remain uncertain. (Full Review)
| Marker | Target | Why |
|---|---|---|
| G6PD activity | Assay normal range; no ozone-specific optimum | G6PD: glucose-6-phosphate dehydrogenase, an enzyme protecting red cells; baseline activity test |
| Hemoglobin and blood-cell counts | Baseline and age/sex laboratory ranges; no established functional target | Anemia and bleeding risk |
| Creatinine and estimated kidney filtration | Stable individual baseline; no established ozone target | Kidney injury |
| Potassium | Usual clinical interval ≈3.5–5.0 mmol/L; local range governs; no ozone-specific optimum | Rhythm risk |
| Bilirubin, lactate dehydrogenase, haptoglobin | Baseline and changes; no ozone-specific target | Suspected red-cell breakdown |
| Clotting tests | Treatment-specific if anticoagulated; no ozone-specific optimum | Bleeding context; selected by drugs, liver disease and circuit anticoagulant |
| Blood pressure and pulse | Resting baseline and session changes; no ozone-specific optimum | Infusion tolerance |
| Disease-specific function | Predefined meaningful baseline change; no universal ozone target | Clinical benefit; same validated instrument or task |
Cadence: Proposed, not validated: baseline; symptoms/vital signs each session; blood count, kidney function and potassium after 1–2 sessions and at completion, earlier if symptoms arise. Function: 3–5 weeks and 1–3 months after stopping; red-cell breakdown tests symptom-triggered.